Research programme: oral cavity disorder biotherapeutics - Intrexon/Oragenics
Latest Information Update: 10 Jul 2015
At a glance
- Originator Intrexon Corporation; Oragenics Inc
- Mechanism of Action Mucoprotein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mouth disorders; Stomatitis
Most Recent Events
- 10 Jun 2015 Early research in Stomatitis and other Mouth disorders in USA (unspecified route)